
Steve Worland, Ph.D.
Steve Worland, Ph.D., serves as the CEO of Atomwise, where he leads efforts to transform drug discovery through AI and molecular science. With over three decades of experience in biotech leadership and therapeutic innovation, he has guided teams from early discovery to approved medicines, including contributions to Paxlovid® and Inlyta®.
Career Milestones
- Steve Worland, CEO of Atomwise, has over three decades of experience in biotech leadership and therapeutic innovation.
- He co-founded eFFECTOR Therapeutics in 2012, leading it to become a clinical-stage biopharmaceutical company.
- Prior to that, he served as CEO of Anadys Pharmaceuticals, guiding the company through its 2011 acquisition by Roche.
- His scientific research has contributed to the discovery and development of approved medicines like Paxlovid® and Inlyta®.
- These achievements underscore his commitment to advancing drug discovery through scientific and entrepreneurial leadership.
About Atomwise
Atomwise, founded in 2012, is an AI-driven pharmaceutical company revolutionizing small molecule drug discovery. They help pharmaceutical companies, biotech firms, and academic researchers by accelerating drug discovery and optimizing drug candidates. Their core feature, AtomNet® technology, uses deep learning to screen billions of compounds, predicting molecular interactions. Benefits include faster, more cost-effective drug discovery and improved drug design.